AbbVie Inc. (ABBV) — closed signal from December 18, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 18, 2026.
Predicted vs. what happened
What happened
Reached 53% of the predicted growth at its peak, without hitting the target.
The thesis — published December 18, 2025
The stock looks like a cautious bounce, not a clear long-term trend. Analysts disagree-one cut the price target while another raised it-so the likely outcome is sideways gains. A short-term momentum reading is very low but the short-term trend signal still looks weak, so gains may come slowly over a few months. Start small and wait for clearer strength.
Primary drivers
- Analyst upgrade vs target cut supports a sideways rebound
- Very low momentum reading can trigger a short-term rebound
- Money moving into healthcare could help amid tech swings
- Positive drug pipeline talk lifts sentiment despite weak fundamentals
How it played out
ABBV: target was not reached
Lyra published ABBV at $225.12 on 2025-12-18 with expected growth of 10%. The thesis called it a cautious bounce, not a clear long-term trend. It pointed to mixed analyst signals, a very low momentum reading, possible healthcare inflows, and positive drug pipeline talk.
Inside the window, ABBV rose to a peak of $237.11 on 2026-03-04, a 5.3% gain. It stayed below the $247.63 target and never reached it. By 2026-03-18, it ended at $208.34. The thesis partially played out because the stock did rebound, but the move fell short and then faded.
What happened during the window
On 2026-02-04, AbbVie reported fourth-quarter results with revenue of $16.62 billion and adjusted earnings of $2.71 per share. The same day, coverage reported that the stock fell after the release despite the beat.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.